BRKR Bruker Corporation

At Pittcon 2006, Bruker AXS Inc. today launches its new S8 TIGER(TM) X-ray spectrometer for high-performance elemental analysis in various industrial applications, including petrochemistry, cement and mining. The S8 TIGER wavelength dispersive X-ray fluorescence (WDXRF) spectrometer is an innovative high-end system with numerous new and unique advantages, complementing Bruker AXS' well established S4 and S2 lines of XRF systems. The S8 TIGER analyzes all elements from Beryllium to Uranium in a wide variety of sample types. It is designed for demanding applications in industrial process and quality control, and as a powerful elemental analysis tool in research and development departments. Unique features of the S8 TIGER include TouchControl(TM) and SampleCare(TM), combining extreme ease of use and robust reliability with cutting-edge analytical performance. TouchControl responds to customer requests for facile and fail-safe operation. By using an integrated touch screen and dedicated user interface, TouchControl defines a new standard in ease of use for a high-end XRF system. This enables our industrial customers to deploy the S8 TIGER in a manner where untrained users can operate the instrument after receiving only brief instructions. The unique SampleCare feature automatically recognizes liquid samples and its integrated protection seal protects the S8 TIGER against all kinds of contamination, ensuring maximum uptime and availability. The outstanding analytical performance of the S8 TIGER results from the innovative optimized X-ray optics. While the new high-intensity X-ray tube excites the sample even more efficiently, novel analyzer crystals have been developed for different elements and specific applications in order to improve detection limits, precision and resolution. Dr. Heiko Ress, XRF Marketing Manager for Bruker AXS, comments: "With the new intuitive TouchControl operation of our S8 TIGER, the required training for occasional and inexperienced users is absolutely minimized. Its combination with our new SampleCare protection leads to unrivalled fail-safe operation, and provides our industrial customers with a faster return on their investment. In good Bruker AXS tradition, all these innovative ease of use and uptime features, plus the high analytical performance come in a very compact, attractive industrial design. The new S8 TIGER is clearly in a class of its own." Pittcon 2006, the 57th Pittsburgh Conference and Exposition on Analytical Chemistry and Applied Spectroscopy, is being held from March 13-16 in Orlando, Florida in the Orange County Convention Center. The product introduced here will be exhibited at the Bruker AXS booth #3155. ABOUT BRUKER BIOSCIENCES (NASDAQ: BRKR) Bruker BioSciences Corporation, headquartered in Billerica, Massachusetts, is the publicly traded parent company of Bruker Daltonics Inc. and Bruker AXS Inc. Bruker AXS is a leading developer and provider of life science, materials research and industrial X-ray analysis tools. Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. Bruker Daltonics also offers a broad line of nuclear, biological and chemical (NBC) detection products for defense and homeland security. For more information, please visit www.bruker-biosciences.com. CAUTIONARY STATEMENT Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of the Company's products, exposure to currency fluctuations, changes in governmental regulations, capital spending and government funding policies, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our respective annual reports on Form 10-K, our most recent quarterly reports on Form 10-Q, and our current reports on Form 8-K. We disclaim any intent or obligation to update these forward-looking statements.